Effect of relaxation therapy on benzodiazepine use in patients with medically unexplained symptoms

Table 3 Factors related to decreased benzodiazepines use (n = 42)

Independent Variables	Comparison	Crude analysis		Adjusted analysis^a		Adjusted analysis^b
Independent Variables	Comparison	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
Dose used	DAP ^d120 mg/month increase	0.48 (0.13–1.79)	0.27	0.45 (0.11–1.78)	0.25	0.25 (0.04–1.62)	0.15
Duration since use	≦6 months vs 6 months<	0.06 (0.01–0.36)	< 0.01	0.04 (0.01–0.29)	< 0.01	0.04 (0.01–0.37)	< 0.01
Concomitant use of antidepressants	Yes vs no	1.66 (0.31–9.05)	0.56	1.26 (0.18–8.88)	0.81	2.32 (0.20–26.10)	0.49
Use of short-acting BZD^c	Yes vs no	2.54 (0.41–15.90)	0.32	2.53 (0.38–16.60)	0.33	5.05 (0.48–53.10)	0.18

^aAdjusted for sex and age. ^bAdjusted for sex, age, and relaxation therapy modality. ^cBenzodiazepine. ^d Diazepam. OR odds ratio, CI confidence interval

ISSN: 1751-0759